– USA, CA – BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that veteran dental industry executive Harold C. Flynn Jr. will become President and Chief Executive Officer, effective July 13, 2015. The current President and CEO Jeffrey M. Nugent will step down at that time.

Flynn, 50, has more than 25 years of senior executive experience in the dental, hematology and diagnostics markets. Since 2007, he has been President of Zimmer Dental, a leading manufacturer and provider of medical devices for the dental market including dental implants, prosthetics, and a range of other oral rehabilitation products. Zimmer Dental is a division of Zimmer Holdings Inc. (NYSE and SIX: ZMH).

“Harold’s dental industry and medical device experience make him a natural fit to lead BIOLASE,” said Chairman Paul N. Clark. “He is a strategic thinker who has successfully managed global functions at Zimmer, much like he will do at BIOLASE. Harold has demonstrated an ability to build successful management teams, drive growth, and spur innovation at a number of companies, large and small. We are confident he is the right choice to continue the transformation of BIOLASE and we look forward to him joining the team.”

Clark added, “Jeff agreed as a Board member last summer to step in to help us, and I would like to thank him for the leadership and commitment he has shown in beginning the transformation of BIOLASE. He strengthened our leadership team and improved quality. We are grateful for his continued support and work with BIOLASE through the transition.”

Prior to Zimmer, from 2004-2007, Flynn was Divisional Vice President and General Manager at Abbott Hematology, a division of Abbott Laboratories, where he provided strategic leadership, strengthened the product pipeline, and rebuilt the leadership team.

Previously, Flynn spent 14 years in a variety of positions of increasing responsibility at IDEXX Laboratories, a global leader in veterinary, food and environmental diagnostics.

“This is a very important and exciting time of transformation at BIOLASE. I look forward to helping BIOLASE achieve its considerable potential,” Flynn said. “With a demonstrated legacy of market-leading innovation providing patient-centric solutions and new laser-based treatment modalities, BIOLASE is well positioned to significantly expand its penetration and share in the markets it serves.”

Flynn has a Bachelor of Science degree in Electrical Engineering from the University of Maine at Orono. He holds patents in hematology and implantable devices for dentistry. He lives with his family in Encinitas, CA.

About BIOLASE, Inc.

BIOLASE, Inc. is a medical device company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment, CAD/CAM intraoral scanners, and in-office milling machines and 3D printers. BIOLASE’s products are focused on technologies that advance the practice of dentistry to both the dentist and their patients. The Company’s proprietary laser products incorporate approximately 200 patented and 150 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold approximately 28,300 laser systems. Laser products under development address the Company’s core dental market and other adjacent medical and consumer markets.

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

here the original post =>

Comments are closed.